Bevacizumab in Combination With Paclitaxel/Carboplatin + IBI305 in Combination with Paclitaxel/Carboplatin
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedAbout Bevacizumab in Combination With Paclitaxel/Carboplatin + IBI305 in Combination with Paclitaxel/Carboplatin
Bevacizumab in Combination With Paclitaxel/Carboplatin + IBI305 in Combination with Paclitaxel/Carboplatin is a phase 3 stage product being developed by WuXi Biologics for NSCLC. The current trial status is completed. This product is registered under clinical trial identifier NCT02954172. Target conditions include NSCLC.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02954172 | Phase 3 | Completed |
Competing Products
20 competing products in NSCLC